Sign In
Buy IMUX
$14.17
-0.470 (-3.21%)
At Close: Jun 03, 2026
Immunic Post-Readout: Reiterating Strong Buy As Big Drop Appears Unwarranted
05:51pm, Monday, 09'th Jun 2025
Immunic, Inc.'s CALLIPER study showed vidofludimus calcium reduced disability progression by 30% in PPMS patients, despite modest MRI results, suggesting strong neuroprotective effects. IMUX stock's s
Immunic completes Phase 3 multiple sclerosis trial enrollment - ICYMI
09:35am, Saturday, 07'th Jun 2025
Immunic Inc (NASDAQ:IMUX)'s chief medical officer Dr Andreas Muehler talked with Proactive about the successful completion of patient enrollment for its Phase 3 ENSURE program targeting relapsing mult
Immunic completes patient enrollment in Phase 3 relapsing multiple sclerosis trials
08:32am, Thursday, 05'th Jun 2025
Immunic Inc (NASDAQ:IMUX) has announced the completion of enrollment for both phase 3 ENSURE trials of its lead asset, vidofludimus calcium (IMU-838), in relapsing multiple sclerosis (RMS). The ENSUR
– Enrollment Completed for Both Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Top-Line Data Expected End of 2026 – – Additional Data from Phase 2 CALLIPER Trial
Immunic raises $65M in public offering to fund clinical trials
04:08pm, Tuesday, 03'rd Jun 2025
Immunic Inc (NASDAQ:IMUX), a biotechnology firm focused on developing oral therapies for chronic inflammatory and autoimmune diseases, on Tuesday closed a previously announced underwritten public offe
Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering
04:01pm, Tuesday, 03'rd Jun 2025
NEW YORK , June 3, 2025 /PRNewswire/ -- Immunic, Inc. ("Immunic" or the "Company") (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapi
Immunic to Participate in Investor, Scientific and Industry Conferences in June
06:30am, Monday, 02'nd Jun 2025
NEW YORK , June 2, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammat
Immunic unveils pricing of $65M underwritten public offering
08:22am, Thursday, 29'th May 2025
Immunic Inc (NASDAQ:IMUX) has announced the pricing of an oversubscribed underwritten public offering that is expected to generate approximately $65 million in gross proceeds, which the company plans
Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering
07:05am, Thursday, 29'th May 2025
NEW YORK , May 29, 2025 /PRNewswire/ -- Immunic, Inc. ("Immunic" or the "Company") (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapi
Immunic, Inc. Announces Proposed Public Offering
04:02pm, Wednesday, 28'th May 2025
NEW YORK , May 28, 2025 /PRNewswire/ -- Immunic, Inc. ("Immunic" or the "Company") (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapi
Immunic to Participate in Scientific and Industry Conferences in May
06:30am, Friday, 02'nd May 2025
NEW YORK , May 2, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammato
Immunic reports reduced disability worsening in progressive multiple sclerosis trial
09:36am, Wednesday, 30'th Apr 2025
Immunic Inc (NASDAQ:IMUX) has reported promising results from its Phase 2 CALLIPER trial of vidofludimus calcium, which showed a 30% reduction in the risk of 24-week confirmed disability worsening in
– Reduced Relative Risk of 24-Week Confirmed Disability Worsening Events by 20% in Overall Study Population Compared to Placebo; Even More Prominent 30% Reduction in High Unmet Need Population of Pr
Immunic: A Strong Buy With Imminent Data Readout That Should Send Shares Higher
02:09am, Monday, 28'th Apr 2025
Immunic's lead asset, vidofludimus calcium, shows promise in MS trials, with positive interim results and potential for commercialization if upcoming catalysts deliver. Despite high volatility and rec
Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments
01:00pm, Thursday, 10'th Apr 2025
NEW YORK , April 10, 2025 /PRNewswire/ -- Immunic, Inc. ("Immunic" or the "Company") (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule ther
